A comparison of the new indicator test for sudomotor function (Neuropad®) with the vibration perception threshold and the clinical examination in the diagnosis of peripheral neuropathy in subjects with type 2 diabetes

Experimental and Clinical Endocrinology and Diabetes

Volumn 116, Issue 2, 2008, Pages 135-138

  Papanas, N ^a,c   Papatheodorou, K ^a   Papazoglou, D ^a   Monastiriotis, C ^a   Christakidis, D ^b   Maltezos, E ^a  

^a DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

^b DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

^c NONE   (Greece)

Author keywords

Diabetes mellitus; Diabetic foot; Diabetic neuropathy; Sudomotor function

Indexed keywords

ADULT; ARTICLE; AUTONOMIC NERVOUS SYSTEM; CLINICAL EXAMINATION; COMPARATIVE STUDY; CORRELATION ANALYSIS; DEVICE; DIABETIC PATIENT; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PERCEPTIVE THRESHOLD; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; SCORING SYSTEM; SENSITIVITY ANALYSIS; SENSITIVITY AND SPECIFICITY; SUDOMOTOR FUNCTION; VIBRATION SENSE;

AGED; DIABETES MELLITUS, TYPE 2; DIABETIC NEUROPATHIES; FEMALE; FOOT; HUMANS; MALE; MIDDLE AGED; NEUROLOGIC EXAMINATION; PERCEPTION; PSYCHOMOTOR PERFORMANCE; SENSITIVITY AND SPECIFICITY; SENSORY THRESHOLDS; VIBRATION;

EID: 40549137491     PISSN: 09477349     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-984455     Document Type: Article

References (30)

1. Abbott CA, Vileikyte L, Williamson S, Carrington AL, Boulton AJ. Multicenter study of the incidence of and predictive risk factors for diabetic neuropathic foot ulceration. Diabetes Care 1998; 21: 1071-1075
2. Abbott CA, Carrington AL, Ashe H, Bath S, Every LC, Griffiths J et al. The North-West Diabetes Foot Care Study: incidence of, and risk factors for, new diabetic foot ulceration in a community-based patient cohort. Diabet Med 2002; 19: 377-384
3. Armstrong DG, Lavery LA, Vela SA, Quebedeaux TL, Fleischli JG. Choosing a practical screening instrument to identify patients at risk for diabetic foot ulceration. Arch Intern Med 1998; 158: 289-292
4. Boulton AJM, Kirsner RS, Vileikyte L. Neuropathic diabetic foot ulcers. N Engl J Med 2004; 351: 48-55
5. Boulton AJ, Vinik AI, Arezzo JC, Bril V, Feldman EL, Freeman R, Malik RA, Maser RE, Sosenko JM, Ziegler D, American Diabetes Association. Diabetic neuropathies: a statement by the American Diabetes Association. Diabetes Care 2005; 28: 956-962
6. Braune HJ, Horter C. Sympathetic skin response in diabetic neuropathy: a prospective clinical and neurophysiological trial on 100 patients. J Neurol Sci 1996; 138: 120-124
7. Bril V, Perkins BA. Comparison of vibration perception thresholds obtained with the Neurothesiometer and the CASE IV and relationship to nerve conduction studies. Diabet Med 2002; 19: 661-666
8. Davis EA, Jones TW, Walsh P, Byrne GC. The use of biothesiometry to detect neuropathy in children and adolescents with IDDM. Diabetes Care 1997; 20: 1448-1453
9. Edmonds ME. The diabetic foot, 2003. Diabetes Metab Res Rev 2004; 20 Suppl 1:S9-S12
10. Haslbeck KM, Schleicher E, Bierhaus A, Nawroth P, Haslbeck M, Neundörfer B et al. The AGE/RAGE/NF-(kappa) B pathway may contribute to the pathogenesis of polyneuropathy in impaired glucose tolerance (IGT). Exp Clin Endocrinol Diabetes 2005; 113: 288-291
11. Jurado J, Ybarra J, Pou JM. Isolated use of vibration perception thresholds and Semmes Weinstein monofilament in diagnosing diabetic polyneuropathy: "the North Catalonia diabetes study". Nurs Clin North Am 2007; 42: 59-66
12. Kumar S, Fernando DJ, Veves A, Knowles EA, Young MJ, Boulton AJ. Semmes-Weinstein monofilaments: a simple, effective and inexpensive screening device for identifying diabetic patients at risk of foot ulceration. Diabetes Res Clin Pract 1991; 13: 63-67
13. Manes C, Mikoudi K, Sossidou E, Pigas G, Karagianni D, Skoutas D, Fotiadis S. Evaluation of a new indicator plaster in identifying diabetic patients at risk of foot ulceration. Diabetologia 2004; 47 (Suppl 1):A376
14. Marinou K, Maggana S, Liatis S, Nikolopoulos A, Diakoumopoulou E, Tentolouris N et al. Usefulness of the indicator plaster Neuropad for the diagnosis of peripheral and autonomic neuropathy in patients with diabetes mellitus. Diabetologia 2005; 48 (Suppl 1):A995
15. Paisley AN, Abbott CA, van Schie CH, Boulton AJ. A comparison of the Neuropen against standard quantitative sensory-threshold measures for assessing peripheral nerve function. Diabet Med 2002; 19: 400-405
16. Papanas N, Papatheodorou K, Christakidis D, Papazoglou D, Giassakis G, Piperidou H et al. Evaluation of a new indicator test for sudomotor function (Neuropad) in the diagnosis of peripheral neuropathy in type 2 diabetic patients. Exp Clin Endocrinol Diabetes 2005; 113: 195-198
17. Papanas N, Papatheodorou K, Papazoglou D, Christakidis D, Monastiriotis C, Maltezos E. Reproducibility of the new indicator test for sudomotor function (Neuropad) in patients with type 2 diabetes mellitus: short communication. Exp Clin Endocrinol Diabetes 2005b; 113: 577-581
18. Papanas N, Gries A, Maltezos E, Zick R. The steel ball-bearing test: a new test for evaluating protective sensation in the diabetic foot. Diabetologia 2006; 49: 739-743
19. Papanas N, Giassakis G, Papatheodorou K, Papazoglou D, Monastiriotis C, Christakidis D et al. Use of the new indicator test (Neuropad) for the assessment of the staged severity of neuropathy in type 2 diabetic patients. Exp Clin Endocrinol Diabetes 2007; 115: 58-61
20. Papanas N, Papatheodorou K, Papazoglou D, Christakidis D, Monastiriotis C, Maltezos E. The new indicator test (Neuropad): a valuable diagnostic tool for small-fiber impairment in patients with type 2 diabetes. Diabetes Educ 2007b; 33: 257-258 260, 262 passim.
21. Papanas N, Papatheodorou K, Papazoglou D, Kotsiou S, Christakidis D, Maltezos E. An insertion/deletion polymorphism in the alpha2b adrenoceptor gene is associated with peripheral neuropathy in patients with type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes 2007c; 115: 327-330
22. Pham H, Armstrong DG, Harvey C, Harkless LB, Giurini JM, Veves A. Screening techniques to identify people at high risk for diabetic foot ulceration: a prospective multicenter trial. Diabetes Care 2000; 23: 606-611
23. Rith-Najarian SJ, Stolusky T, Gohdes DM. Identifying diabetic patients at high risk for lower-extremity amputation in a primary health care setting. A prospective evaluation of simple screening criteria. Diabetes Care 1992; 15: 1386-1389
24. Shimada H, Kihara M, Kosaka S, Ikeda H, Kawabata K, Tsutada T et al. Comparison of SSR and QSART in early diabetic neuropathy: value of length-dependent pattern in QSART Auton Neurosci 2001; 92: 72-75
25. Veves A, Manes C, Munay HJ, Young MJ, Boulton AJ. Painful neuropathy and foot ulceration in diabetic patients. Diabetes Care 1993; 16: 1187-1189
26. Vileikyte L, Hutchings G, Hollis S, Boulton AJ. The tactile circumferential discriminator. A new, simple screening device to identify diabetic patients at risk of foot ulceration. Diabetes Care 1997; 20: 623-626
27. Young MJ, Boulton AJ, MacLeod AF, Williams DR, Sonksen PH. A multicentre study of the prevalence of diabetic peripheral neuropathy in the United Kingdom hospital clinic population. Diabetologia 1993; 36: 150-154
28. Young MJ, Breddy JL, Veves A, Boulton AJ. The prediction of diabetic neuropathic foot ulceration using vibration perception thresholds. A prospective study. Diabetes Care 1994; 17: 557-560
29. Zick R, Schäper T, Deeters U. Periphere diabetische Neuropathic Die Schweißsekretion am Fuß messen. Klinikarzt 2003; 32: 192-194
30. Zimny S, Pfohl M. Healing times and prediction of wound healing in neuropathic diabetic foot ulcers: a prospective study. Exp Clin Endocrinol Diabetes 2005; 113: 90-93